Theratechnologies Inc.

275 articles with Theratechnologies Inc.

• Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model

  3/14/2023

  Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced that new data will be presented demonstrating the promise of its SORT1+ Technology™ platform of proprietary peptides, and of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), in enabling targeted delivery of anticancer therapy.

• Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price - March 07, 2023

  3/7/2023

  Theratechnologies Inc. announced receipt of a notification letter from The Nasdaq Stock Market LLC dated March 3, 2023, advising that the Company was not in compliance with Listing Rule 5550 as the bid price of the Company’s listed securities had closed at less than US$1.00 per share over the last 30 consecutive business days from January 19, 2023 to March 2, 2023.

• Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022

  2/28/2023

  Theratechnologies Inc. today reported business highlights and financial results for the fourth quarter and full year ended November 30, 2022. All figures are in U.S. dollars unless otherwise stated.

• Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management

  2/28/2023

  Theratechnologies Inc. today announced that it has entered into a first amendment to its credit agreement dated July 20, 2022 (the “Credit Facility”) with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, “Marathon”).

• Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV

  2/22/2023

  Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in people with HIV (PWHIV) by reducing excess visceral abdominal fat (EVAF).

• Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

  2/14/2023

  Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023.

• World Orphan Drug Alliance Announces Agreement with Theratechnologies for the Distribution of EGRIFTA SV

  1/5/2023

  The World Orphan Drug Alliance, a global alliance of commercial distributors focused on providing access to treatments for rare diseases and specialty medicines in complex and underserved markets around the world, announced a long-term, multi-territorial distribution agreement with Theratechnologies Inc. for EGRIFTA SV® in 41 countries.

• Open Letter to Shareholders from CEO Paul Levesque

  1/4/2023

  Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. All amounts are in U.S. dollars unless otherwise stated.

• Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays

  10/26/2022

  Theratechnologies Inc. study demonstrating high expression of sortilin 1 (SORT1) in several solid tumors when compared to normal tissues, to be presented as a poster at the 34th European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI), and the American Association for Cancer Research (AACR) Symposium on molecular targets and cancer therapeutics being held October 26-28, 2022, in Barcelona, Spain.

• Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update

  10/13/2022

  Theratechnologies Inc. today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August 31, 2022. All figures are in U.S. dollars unless otherwise stated.

• Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium

  10/12/2022

  Theratechnologies Inc. today announced that the Company will present data from tissue microarrays showing high expression of SORT1, the target for Theratechnologies’ oncology platform, in several cancer types.

• Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population

  10/3/2022

  Theratechnologies Inc. announced that the United States Food and Drug Administration approved Trogarzo® for administration by intravenous push, a method by which the undiluted medication is “pushed” by syringe for faster administration into the body’s circulation.

• 

  FDA Action Alert: Theratechnologies, Alnylam, scPharmaceuticals and More

  10/3/2022

  Theratechnologies’ Trogarzo for HIV, Alnylam’s Lumasiran for advanced primary hyperoxaluria, scPharmaceuticals' Furoscix for heart failure and more. Here's a look at the FDA's October calendar.

• Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update

  9/26/2022

  Theratechnologies Inc. today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13, 2022.

• Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference

  9/19/2022

  Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), today announced that Paul Levesque, President and Chief Executive Officer, will participate on the “Novel Targets in Oncology: Risk vs. Reward” panel, at the Cantor Oncology, Hematology & HemeOnc Conference to be held at the New York Palace Hotel, on Wednesday, September 28, 2022, at 9:00 a.m. ET, in New York City.

• Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth

  9/12/2022

  Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC) stem-like cells’ (CSCs) tumor growth.

• Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference

  8/2/2022

  Theratechnologies Inc. will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1:00 p.m. ET.

• Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens

  7/28/2022

  Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced data from two poster presentations at the 24th International AIDS Conference, being held from July 29 to August 2 in Montreal, Canada and virtually.

• Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement

  7/27/2022

  Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced that it has received funding of $40 million under the terms of its credit agreement with affiliated funds of Marathon Asset Management.

• Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update

  7/14/2022

  Theratechnologies Inc. today reported business highlights and financial results for the second quarter and first half of fiscal year 2022 ended May 31, 2022. All figures are in U.S. dollars unless otherwise stated.